文献速递肺栓塞与肺血管病

靶向肽基脯氨酰异构酶1治疗实验性肺动脉高压

Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension.
PubMed 文献 · Eur Respir J · 2022-08-25

本研究探讨Pin1在肺动脉高压(PAH)中的作用,发现Pin1在实验性PAH模型及患者肺动脉平滑肌细胞中表达升高;抑制Pin1可诱导凋亡、减少增殖,并降低HIF-α和STAT等转录因子活性;Juglone给药可降低肺血管阻力、改善右心功能及肺血管和心脏重构。

要点

  • Pin1在实验性PAH和临床PAH患者肺动脉平滑肌细胞中表达显著升高。
  • 抑制Pin1可诱导人肺血管细胞凋亡并减少增殖,降低HIF-α和STAT活性。
  • Juglone在Sugen/缺氧大鼠和小鼠慢性缺氧模型中改善肺血管阻力、右心功能及重构。

核心结论

  • 靶向Pin1的小分子抑制剂Juglone可能成为PAH及继发性右心疾病的有前景的治疗策略。

研究设计与样本

  • 实验性研究,使用缺氧诱导小鼠和Sugen/缺氧诱导大鼠肺动脉高压模型,以及临床PAH患者肺动脉平滑肌细胞。

主要发现

  • Pin1在实验性肺动脉高压和临床PAH患者肺动脉平滑肌细胞中表达显著升高。
  • Juglone处理或siRNA敲低Pin1可诱导人肺血管细胞凋亡并减少增殖。
  • 生长因子刺激诱导Pin1表达,抑制Pin1降低HIF-α和STAT等PAH相关转录因子活性。
  • Juglone给药降低Sugen/缺氧大鼠肺动脉高压模型的肺血管阻力,增强右心室功能,改善肺血管和心脏重构,并在小鼠慢性缺氧诱导的肺动脉高压模型中改善肺血管和心脏重构。

临床怎么用

  • 本研究为实验性研究,尚未提供临床推荐;但提示Pin1可能作为PAH治疗的潜在靶点,Juglone值得进一步转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive disease characterised by pro-proliferative and anti-apoptotic phenotype in vascular cells, leading to pulmonary vascular remodelling and right heart failure. Peptidyl-prolyl cis/trans isomerase, NIMA interacting 1 (Pin1), a highly conserved enzyme, which binds to and catalyses the isomerisation of specific phosphorylated Ser/Thr-Pro motifs, acts as a molecular switch in multiple coordinated cellular processes. We hypothesised that Pin1 plays a substantial role in PAH, and its inhibition with a natural organic compound, Juglone, would reverse experimental pulmonary hypertension. RESULTS: We demonstrated that the expression of Pin1 was markedly elevated in experimental pulmonary hypertension (i.e. hypoxia-induced mouse and Sugen/hypoxia-induced rat models) and pulmonary arterial smooth muscle cells of patients with clinical PAH. In vitro Pin1 inhibition by either Juglone treatment or short interfering RNA knockdown resulted in an induction of apoptosis and decrease in proliferation of human pulmonary vascular cells. Stimulation with growth factors induced Pin1 expression, while its inhibition reduced the activity of numerous PAH-related transcription factors, such as hypoxia-inducible factor (HIF)-α and signal transducer and activator of transcription (STAT). Juglone administration lowered pulmonary vascular resistance, enhanced right ventribular function, improved pulmonary vascular and cardiac remodelling in the Sugen/hypoxia rat model of PAH and the chronic hypoxia-induced pulmonary hypertension model in mice. CONCLUSION: Our study demonstrates that targeting of Pin1 with small molecule inhibitor, Juglone, might be an attractive future therapeutic strategy for PAH and right heart disease secondary to PAH.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Rai N, Sydykov A, Kojonazarov B, et al. Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension. Eur Respir J. 2022. PMID: 35058248. doi:10.1183/13993003.01698-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。